Skip to main content
. 2021 Feb 24;106(8):e3221–e3234. doi: 10.1210/clinem/dgab108

Figure 3.

Figure 3.

Reproductive hormone levels in women receiving placebo or elinzanetant during the study. A, C, and E, The median averaged across all time points during cycles 1 (C1) and 2 (C2) in A, serum luteinizing hormone (LH; IU/L); C, follicle-stimulating hormone (FSH; IU/L); and E, estradiol (pmol/L) in women after placebo (N = 8, red), elinzanetant 40 mg (N = 7, blue), 80 mg (N = 8, green), and 120 mg (N = 8, orange). Data in graphs depict within-participant paired raw data and the group median and interquartile range. **P less than .01, Wilcoxon matched-pairs signed rank test. B, D, and F, The median change averaged across all time points between cycles 1 and 2 in B, serum LH (IU/L); D, FSH (IU/L); and F, estradiol (pmol/L) in healthy women after placebo (N = 8, red), elinzanetant 40 mg (N = 7, blue), 80 mg (N = 8, green), and 120 mg (N = 8, orange). *P less than .05, Wilcoxon rank sum test. G, The median change from baseline on day 21 or 22 in serum progesterone (nmol/L) in healthy women after placebo (N = 8, red), elinzanetant 40 mg (N = 7, blue), 80 mg (N = 8, green), and 120 mg (N = 8, orange). Data in graphs depict within-participant paired raw data and the group median and interquartile range. *P less than .05, Wilcoxon matched-pairs signed rank test (comparing cycle 1 and cycle 2) and Wilcoxon rank sum test (comparing placebo vs elinzanetant). H, The median change from baseline on day 21 or 22 in serum progesterone (nmol/L) in healthy women after placebo (N = 8, red), elinzanetant 40 mg (N = 7, blue), 80 mg (N = 8, green), and 120 mg (N = 8, orange). *P less than .05, Wilcoxon rank sum test.